Edesa Biotech Inc
EDSA
Company Profile
Business description
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Contact
100 Spy Court
MarkhamONL3R 5H6
CANT: +1 289 800-9600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2025
Employees
16
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,816.40 | 58.90 | -0.66% |
CAC 40 | 7,722.09 | 44.12 | -0.57% |
DAX 40 | 24,009.38 | 50.91 | -0.21% |
Dow JONES (US) | 44,254.78 | 231.49 | 0.53% |
FTSE 100 | 8,926.55 | 11.77 | -0.13% |
HKSE | 24,517.76 | 72.36 | -0.29% |
NASDAQ | 20,730.49 | 52.69 | 0.25% |
Nikkei 225 | 39,663.40 | 14.62 | -0.04% |
NZX 50 Index | 12,754.59 | 64.96 | 0.51% |
S&P 500 | 6,263.70 | 19.94 | 0.32% |
S&P/ASX 200 | 8,561.80 | 68.50 | -0.79% |
SSE Composite Index | 3,503.78 | 1.22 | -0.03% |